ArticleJCO precision oncology2019
Response to Selective RET Inhibition With LOXO-292 in a Patient With
Article in JCO precision oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.Neuro-oncology · 2022Guideline
- Intracranial Activity of Selpercatinib in Chinese Patients With AdvancedJCO precision oncology · 2023Trial
- Selpercatinib in Patients WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Intracranial Efficacy of Selpercatinib inClinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Article
- Development and Characterization of a Patient-DerivedJTO clinical and research reports · 2026Article
- Article
- Review
- Review
- A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases.International journal of molecular sciences · 2024Review
- Salvage Therapy With Selpercatinib forJTO clinical and research reports · 2023Article
- Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.Nature cancer · 2023Article
- Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model.Biomolecules · 2023Article
- Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023Article
- Structural and dynamic determinants for highly selective RET kinase inhibition reveal cryptic druggability.Journal of advanced research · 2023Article
- Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era.International journal of molecular sciences · 2022Review
- Response to Pralsetinib Observed in Meningeal-MetastaticJTO clinical and research reports · 2022Article
- Precision therapy for RET-altered cancers with RET inhibitors.Trends in cancer · 2021Review
- Epidemiology of brain metastases and leptomeningeal disease.Neuro-oncology · 2021Review
- Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity.Science translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.